Cortexin vs PT-141 (Bremelanotide)
A detailed comparison to help you understand the differences and choose the right peptide for your research goals.
Cortexin
Cortexin is a polypeptide complex derived from pig brain cortex, used clinically in Russia and Eastern Europe for neurological conditions including stroke recovery, traumatic brain injury, and cognitive decline.
Full details →PT-141 (Bremelanotide)
PT-141, also known as Bremelanotide, is a synthetic peptide analog of alpha-melanocyte-stimulating hormone. It is the only FDA-approved treatment for hypoactive sexual desire disorder (HSDD) in premenopausal women.
Full details →Side-by-Side Comparison
| Aspect | Cortexin | PT-141 (Bremelanotide) |
|---|---|---|
| Dose Range | 10 mg–20 mg | 1.8 mg |
| Frequency | 1x daily | Less than daily |
| Cycle Length | 1–2 weeks | 4–12 weeks |
| Route | intramuscular | subcutaneous |
| Mechanism | Contains a mixture of neuropeptides and amino acids that support neuronal metabolism, provide neuroprotection, and enhance synaptic transmission. Specific mechanisms not fully characterized. | PT-141 activates melanocortin receptors (MC3R and MC4R) in the central nervous system, particularly in areas associated with sexual arousal. Unlike PDE5 inhibitors, it works through the nervous system rather than the vascular system. |
| Typical Dosage | Clinical protocols: 10mg intramuscularly once daily for 10-20 days. May be repeated after 3-6 month interval. | FDA-approved dose: 1.75mg administered subcutaneously at least 45 minutes before anticipated sexual activity. Not to be used more than once within 24 hours or more than 8 times per month. |
| Administration | Intramuscular injection. Comes as lyophilized powder requiring reconstitution. Treatment given in courses rather than continuously. | Subcutaneous injection in the abdomen. Available as Vyleesi (commercial product). Research use may involve different dosing protocols. |
| Side Effects | Generally well-tolerated. May cause injection site reactions or mild allergic responses in sensitive individuals. | Common side effects include nausea (40% of users), flushing, headache, and injection site reactions. Transient blood pressure increases may occur. |
| Best For |
What They Have in Common
Cortexin, PT-141 (Bremelanotide) are both commonly used for:
Key Differences
Unique to Cortexin:
Which Has Stronger Evidence?
- Recovery & Healing: Cortexin has stronger research support.
| Goal | Cortexin | PT-141 (Bremelanotide) |
|---|---|---|
| Recovery & Healing | medium | low |
Key Studies
Cortexin
- [Cortexin in the comprehensive therapy of alcoholic encephalopathy].
Zhurnal nevrologii i psikhiatrii imeni S.S. Korsakova, 2026
- Cortexin modulates OPG/RANK/RANKL and TRPC1 expression in cerebral ischemia-reperfusion injury.
Neurological research, 2026
- Neurotropic Effects of Cortexin on Models of Mental and Physical Developmental Delay.
Biomedicines, 2025
PT-141 (Bremelanotide)
- Small Effects, Questionable Outcomes: Bremelanotide for Hypoactive Sexual Desire Disorder.
Journal of sex research, 2024
- Safety Profile of Bremelanotide Across the Clinical Development Program.
Journal of women's health (2002), 2022
- Bremelanotide for Treatment of Female Hypoactive Sexual Desire.
Neurology international, 2022
Ready to Learn More?
Looking for trusted sources?